Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - AeroGen, Inc. (NasdaqNM:AEGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider
Location
1310 Orleans Drive
Sunnyvale, CA 94089
Phone: (408) 543-2400
Fax: (408) 543-2450
Employees (last reported count): 108
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Websites
 ·Home Page
 ·Investor Relations
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 35%
·Over the last 6 months:
 · one insider buy; 10.0K shares (0.1% of insider shares)
 · one insider sell; 155.0K shares
  (2.2% of insider shares)
·Institutional: 34% (52% of float)
(35 institutions)
·Net Inst. Buying: 206.0K shares (+2.93%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
AeroGen, Inc. specializes in the development, manufacture and commercialization of products for the controlled delivery of drugs to the lungs. The Company's core technology consists of a proprietary aerosol generator. The Company is developing products in collaboration with pharmaceutical and biotechnology companies for both respiratory therapy and for the delivery of drugs through the lungs to the bloodstream. The Company is in the development stage and has devoted substantially all of its efforts to the development of products. The Company intends to create and market a respiratory disease product portfolio consisting of its nebulizers and AeroDose inhalers. AeroGen will initially target the AeroDose inhalers for delivery of drugs that are currently administered by nebulizers to the lungs of the young and the elderly. Its initial target diseases are pediatric asthma, chronic obstructive pulmonary disease and cystic fibrosis.
More from Market Guide: Expanded Business Description

Financial Summary
AeroGen specializes in the development, manufacture and commercialization of products for the controlled delivery of drugs to the lungs. For the six months ended 6/30/01, revenues fell 54% to $1.6 million. Net loss applicable to Com. rose 23% to $11.4 million. Revenues reflect a lower level of product development activities. Higher loss reflects an increase in personnel, clinical, marketing, and amortization of goodwill and deferred stock-based compensation costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Jane Shaw, Ph.D., 62
Chairman, CEO
$290K--  
Deborah Karlson, 48
CFO
180K$1.0M
Carol Gamble, 48
VP, Gen. Counsel
200K--  
Michael Klimowicz, 50
VP, Product Devel.
204K1.0M
John Power, 41
VP, European Operations
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AEGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 25-Apr-2001
$3.40 
Recent Price$4.82 
52-Week High
on 15-Nov-2000
$13.938
Daily Volume (3-month avg)34.3K
Daily Volume (10-day avg)6,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change-18.2%
26-Week Change
relative to S&P500
-10.9%
Share-Related Items
Market Capitalization$96.4M
Shares Outstanding20.0M
Float13.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.68 
Earnings (ttm)-$9.83 
Earnings (mrq)-$0.32 
Sales (ttm)$0.29 
Cash (mrq)$2.60 
Valuation Ratios
Price/Book (mrq)1.80 
Price/EarningsN/A 
Price/Sales (ttm)16.41 
Income Statements
Sales (ttm)$3.89M
EBITDA (ttm)-$19.1M
Income available to common (ttm)-$35.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-42.45%
Return on Equity (ttm)-160.98%
Financial Strength
Current Ratio (mrq)16.07 
Debt/Equity (mrq)0 
Total Cash (mrq)$51.9M
Short Interest
As of 8-Aug-2001
Shares Short3,000 
Percent of Float0.0%
Shares Short
(Prior Month)
12.0K
Short Ratio0.18 
Daily Volume17.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.